Switch theme
Sign up to access all valuation multiples
Apeloa Pharmaceutical Co Ltd is a pharmaceutical company. It is engaged in research and development, manufacturing and marketing of APIs formulations and veterinary drugs. It offers products including Ofloxacin, Levofloxacin Hydrochloride, Marbofloxacin, and others.
1997
3.4K+
LTM Revenue $1.7B
LTM EBITDA $234M
$1.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Apeloa Pharmaceutical has a last 12-month revenue of $1.7B and a last 12-month EBITDA of $234M.
In the most recent fiscal year, Apeloa Pharmaceutical achieved revenue of $1.7B and an EBITDA of $249M.
Apeloa Pharmaceutical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Apeloa Pharmaceutical valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.6B | $1.7B | XXX | XXX | XXX |
| Gross Profit | $347M | $406M | XXX | XXX | XXX |
| Gross Margin | 22% | 24% | XXX | XXX | XXX |
| EBITDA | $247M | $249M | XXX | XXX | XXX |
| EBITDA Margin | 16% | 15% | XXX | XXX | XXX |
| Net Profit | $136M | $145M | XXX | XXX | XXX |
| Net Margin | 9% | 9% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Apeloa Pharmaceutical's stock price is CNY 14 (or $2).
Apeloa Pharmaceutical has current market cap of CNY 16.3B (or $2.2B), and EV of CNY 13.6B (or $1.9B).
See Apeloa Pharmaceutical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.9B | $2.2B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Apeloa Pharmaceutical has market cap of $2.2B and EV of $1.9B.
Apeloa Pharmaceutical's trades at 1.1x LTM EV/Revenue multiple, and 8.0x LTM EBITDA.
Analysts estimate Apeloa Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Apeloa Pharmaceutical and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.9B | XXX | XXX | XXX |
| EV/Revenue | 1.1x | XXX | XXX | XXX |
| EV/EBITDA | 7.5x | XXX | XXX | XXX |
| P/E | 15.8x | XXX | XXX | XXX |
| P/E/Growth | 0.9x | XXX | XXX | XXX |
| EV/FCF | 18.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpApeloa Pharmaceutical's NTM/LTM revenue growth is 9%
Apeloa Pharmaceutical's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Apeloa Pharmaceutical's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Apeloa Pharmaceutical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Apeloa Pharmaceutical and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 25% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.5M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 14% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Apeloa Pharmaceutical acquired XXX companies to date.
Last acquisition by Apeloa Pharmaceutical was XXXXXXXX, XXXXX XXXXX XXXXXX . Apeloa Pharmaceutical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Apeloa Pharmaceutical founded? | Apeloa Pharmaceutical was founded in 1997. |
| Where is Apeloa Pharmaceutical headquartered? | Apeloa Pharmaceutical is headquartered in China. |
| How many employees does Apeloa Pharmaceutical have? | As of today, Apeloa Pharmaceutical has 3.4K+ employees. |
| Is Apeloa Pharmaceutical publicy listed? | Yes, Apeloa Pharmaceutical is a public company listed on SHE. |
| What is the stock symbol of Apeloa Pharmaceutical? | Apeloa Pharmaceutical trades under 000739 ticker. |
| When did Apeloa Pharmaceutical go public? | Apeloa Pharmaceutical went public in 1997. |
| Who are competitors of Apeloa Pharmaceutical? | Similar companies to Apeloa Pharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's current market cap is $2.2B |
| What is the current revenue of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12-month revenue is $1.7B. |
| What is the current EBITDA of Apeloa Pharmaceutical? | Apeloa Pharmaceutical's last 12-month EBITDA is $234M. |
| What is the current EV/Revenue multiple of Apeloa Pharmaceutical? | Current revenue multiple of Apeloa Pharmaceutical is 1.1x. |
| What is the current EV/EBITDA multiple of Apeloa Pharmaceutical? | Current EBITDA multiple of Apeloa Pharmaceutical is 8.0x. |
| What is the current revenue growth of Apeloa Pharmaceutical? | Apeloa Pharmaceutical revenue growth between 2023 and 2024 was 5%. |
| Is Apeloa Pharmaceutical profitable? | Yes, Apeloa Pharmaceutical is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
